ArticleThe Journal of clinical investigation2012
Scavenger receptors target glycolipids for natural killer T cell activation.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors.Journal for immunotherapy of cancer · 2025Article
- Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells.JCI insight · 2023Article
- Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.Molecular cancer therapeutics · 2022Article
- Gut Microbiota-Derived Unconventional T Cell Ligands: Contribution to Host Immune Modulation.ImmunoHorizons · 2022Article
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).European journal of immunology · 2021Review
- Immunometabolic factors in adolescent chronic disease are associated with Th1 skewing of invariant Natural Killer T cells.Scientific reports · 2021Observational
- CD36 family members are TCR-independent ligands for CD1 antigen-presenting molecules.Science immunology · 2021Article
- Reading the room: iNKT cells influence B cell responses.Molecular immunology · 2021Review
- Natural Killer T (NKT) Cells and Periodontitis: Potential Regulatory Role of NKT10 Cells.Mediators of inflammation · 2021Review
- Invariant natural killer T cells balance B cell immunity.Immunological reviews · 2021Review
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).European journal of immunology · 2019Article
- Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients.Frontiers in immunology · 2019Article
- Role of lipid transfer proteins in loading CD1 antigen-presenting molecules.Journal of lipid research · 2018Review
- Human blood MAIT cell subsets defined using MR1 tetramers.Immunology and cell biology · 2018Article
- Article
- Immunometabolic Activation of Invariant Natural Killer T Cells.Frontiers in immunology · 2018Review
- The autophagy machinery restrains iNKT cell activation through CD1D1 internalization.Autophagy · 2017Article
- Natural killer T cells in atherosclerosis.Nature reviews. Cardiology · 2017Review
- Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
NKT cells are innate-like T cells with powerful regulatory functions that are a promising target for immunotherapy. The efficacy of glycolipids, such as the prototypic NKT cell antagonist α-galactosylceramide (αGalCer), is currently being evaluated in clinical trials, but little is known about factors that target lipid antigens for CD1d presentation and NKT cell activation in vivo. Lipid uptake via the LDL receptor (LDLR) has been shown for digalactosylceramide; however, whether this pathway contributes to CD1d presentation of other important NKT cell agonists remains unclear. We therefore investigated receptor-mediated uptake pathways for CD1d presentation using a panel of structurally diverse lipid antigens. We found that uptake via scavenger receptors was essential for the CD1d presentation of αGalCer and Sphingomonas glycolipids. Moreover, in vivo NKT cell responses, i.e., cytokine production, proliferation, and NKT cell help for adaptive CD4+ and CD8+ T cells, required the uptake of αGalCer via scavenger receptor A. Importantly, our data indicate that structural characteristics of glycolipids determine their receptor binding and direct individual lipids toward different uptake pathways. These results reveal an important contribution of scavenger receptors in the selection of lipids for CD1d presentation and identify structural motifs that may prove useful for therapeutic NKT cell vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.